← Back to All Filings

INCYTE Exec Sells $535k in Stock via Pre-Arranged 10b5-1 Plan

Low SignificanceNovember 7, 2025 at 4:02:11 PM EST

INCYTE CORP

$INCY4CIK: 0000879169

Subscribe to track INCY

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

INCYTE Exec Sells $535k in Stock via Pre-Arranged 10b5-1 Plan

Company: INCYTE CORP (INCY) Form: 4 | Filed: 2025-11-07 Significance: Low

Insider: Stein Steven H Title: EVP & Chief Medical Officer | Relationship: Officer

Transaction: • Type: Sale (following option exercise) • Shares: 5,233 • Price: $102.20 • Value: $534,813 • Owned After: 102,886

Key Insight: This is a routine, low-value sale conducted under a pre-scheduled 10b5-1 trading plan. The transaction represents a negligible percentage of the company's market cap and is likely for personal financial management rather than a change in outlook.

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: INCYTE CORP (INCY)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: An officer at Incyte conducted a minor, pre-planned sale of stock valued at approximately $535k after exercising options, representing an insignificant fraction of the company's market capitalization.
  • Market Impact: The transaction is unlikely to have any market impact due to its small size and execution under a 10b5-1 plan.

Company Information

FieldValue
CompanyINCYTE CORP
Ticker SymbolINCY
CIK0000879169
IndustrySERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

Insider Information

FieldValue
NameStein Steven H
CIK0001673776
Title/PositionEVP & Chief Medical Officer
RelationshipOfficer

Transaction Details

This filing reports the exercise of stock options and the subsequent sale of the acquired shares. The most relevant market event is the sale.

FieldValue
Form Type4
Transaction Date2025-11-05
Transaction CodeS (Sale)
Security TypeCommon Stock
Shares Involved5,233
Price Per Share$102.20
Total Value$534,812.60
Shares Owned After102,886
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$534,812.60
% of Market Cap0.0026%
Shares Transacted5,233
% of Shares Outstanding0.0027%
Post-Transaction Ownership102,886 shares (0.053% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $20.75 billion, this $535k transaction is financially immaterial.
  • Transaction Significance: The sale represents a negligible percentage of both market cap and shares outstanding, falling far below any threshold for significance. The insider sold less than 5% of their direct holdings.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is too small to influence the stock price. Furthermore, its execution under a 10b5-1 plan, established in advance, strips it of any predictive value regarding the insider's current sentiment.

Volume & Sentiment

  • Expected Volume Impact: None. The transaction size is a tiny fraction of typical daily trading volume for a large-cap stock like INCY.
  • Sentiment Indicator: Neutral. This is a routine 'sell-to-cover' transaction associated with option exercises, common for executive compensation.

Additional Context

Transaction Notes

  • Special Circumstances: The filing confirms the transaction was made pursuant to a Rule 10b5-1 trading plan. This indicates the sale was pre-scheduled and not based on any immediate, non-public information.
Topics:#SECFiling#InsiderTrading#INCY#Incyte#Form4#InsiderSell#StockMarket#Biotech#10b51

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.